Brian Swankoski

Papers

Total Citations

H-Index

About

Brian Swankoski is a leading figure in pharmacovigilance innovation, with a primary research focus on the application of artificial intelligence and automation to drug safety systems. His most cited work, "Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing" (2018, 86 citations), demonstrates his pivotal role in transforming pharmaceutical safety. In this landmark study, Swankoski piloted the use of AI and robotic process automation to automate adverse event case processing—historically the strongest cost driver in pharmacovigilance budgets. His research provided early, compelling evidence that intelligent automation could dramatically improve efficiency and accuracy in safety data management, setting a new standard for the industry. Beyond this foundational paper, Swankoski’s contributions have helped bridge the gap between cutting-edge computational methods and regulatory compliance, making him a sought-after expert in the field. His work continues to shape how pharmaceutical companies approach risk management, offering scalable solutions that reduce human error while accelerating the detection of critical safety signals. For students and researchers interested in the future of drug safety, Swankoski’s research represents a crucial intersection of technology and public health.